Cargando…

Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis

INTRODUCTION: To investigate the effects of hepatic arterial infusion chemotherapy (HAIC) with or without systemic chemotherapy compared to systemic chemotherapy alone in patients with locally advanced hepatocellular carcinoma (HCC). METHODS: Following a registered protocol (PROSPERO 2023 CRD4202338...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyeon-Jong, Lee, Seung Hyuk, Shim, Hyun Jeong, Bang, Hyun Jin, Cho, Sang Hee, Chung, Ik-Joo, Hwang, Eu Chang, Hwang, Jun Eul, Bae, Woo Kyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597692/
https://www.ncbi.nlm.nih.gov/pubmed/37881486
http://dx.doi.org/10.3389/fonc.2023.1265240
_version_ 1785125397796487168
author Kim, Hyeon-Jong
Lee, Seung Hyuk
Shim, Hyun Jeong
Bang, Hyun Jin
Cho, Sang Hee
Chung, Ik-Joo
Hwang, Eu Chang
Hwang, Jun Eul
Bae, Woo Kyun
author_facet Kim, Hyeon-Jong
Lee, Seung Hyuk
Shim, Hyun Jeong
Bang, Hyun Jin
Cho, Sang Hee
Chung, Ik-Joo
Hwang, Eu Chang
Hwang, Jun Eul
Bae, Woo Kyun
author_sort Kim, Hyeon-Jong
collection PubMed
description INTRODUCTION: To investigate the effects of hepatic arterial infusion chemotherapy (HAIC) with or without systemic chemotherapy compared to systemic chemotherapy alone in patients with locally advanced hepatocellular carcinoma (HCC). METHODS: Following a registered protocol (PROSPERO 2023 CRD42023386780 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023386780), a comprehensive search was performed using reputable databases and registries up to December 26, 2022, with no language, publication date, or status restrictions. Only randomized controlled trials (RCTs) investigating the effects of HAIC with or without systemic chemotherapy versus systemic therapy alone were included. The primary outcomes were overall survival (OS), progression-free survival (PFS), and adverse events. The secondary outcomes included the objective response rate (ORR) and disease control rate (DCR). A random-effects model was used, and the certainty of the evidence was rated using GRADE. RESULTS: Seven RCTs involving 1,010 patients were included. All trials utilized sorafenib as the comparator. Five trials (690 patients) compared HAIC plus sorafenib to sorafenib alone, while two trials (320 patients) compared HAIC to sorafenib. The results indicate that HAIC, with or without sorafenib, may increase OS, PFS, and ORR compared with sorafenib alone. HAIC may enhance DCR, but the evidence is very uncertain. Adverse events were comparable between HAIC plus sorafenib and sorafenib alone. However, adverse events might be decreased in HAIC alone. DISCUSSION: HAIC with or without systemic chemotherapy may improve survival outcomes and response rates of patients with HCC. Since the current body of evidence is moderate to very low, more robust randomized trials are needed to confirm the efficacy of HAIC. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=386780, identifier CRD42023386780.
format Online
Article
Text
id pubmed-10597692
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105976922023-10-25 Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis Kim, Hyeon-Jong Lee, Seung Hyuk Shim, Hyun Jeong Bang, Hyun Jin Cho, Sang Hee Chung, Ik-Joo Hwang, Eu Chang Hwang, Jun Eul Bae, Woo Kyun Front Oncol Oncology INTRODUCTION: To investigate the effects of hepatic arterial infusion chemotherapy (HAIC) with or without systemic chemotherapy compared to systemic chemotherapy alone in patients with locally advanced hepatocellular carcinoma (HCC). METHODS: Following a registered protocol (PROSPERO 2023 CRD42023386780 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023386780), a comprehensive search was performed using reputable databases and registries up to December 26, 2022, with no language, publication date, or status restrictions. Only randomized controlled trials (RCTs) investigating the effects of HAIC with or without systemic chemotherapy versus systemic therapy alone were included. The primary outcomes were overall survival (OS), progression-free survival (PFS), and adverse events. The secondary outcomes included the objective response rate (ORR) and disease control rate (DCR). A random-effects model was used, and the certainty of the evidence was rated using GRADE. RESULTS: Seven RCTs involving 1,010 patients were included. All trials utilized sorafenib as the comparator. Five trials (690 patients) compared HAIC plus sorafenib to sorafenib alone, while two trials (320 patients) compared HAIC to sorafenib. The results indicate that HAIC, with or without sorafenib, may increase OS, PFS, and ORR compared with sorafenib alone. HAIC may enhance DCR, but the evidence is very uncertain. Adverse events were comparable between HAIC plus sorafenib and sorafenib alone. However, adverse events might be decreased in HAIC alone. DISCUSSION: HAIC with or without systemic chemotherapy may improve survival outcomes and response rates of patients with HCC. Since the current body of evidence is moderate to very low, more robust randomized trials are needed to confirm the efficacy of HAIC. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=386780, identifier CRD42023386780. Frontiers Media S.A. 2023-10-10 /pmc/articles/PMC10597692/ /pubmed/37881486 http://dx.doi.org/10.3389/fonc.2023.1265240 Text en Copyright © 2023 Kim, Lee, Shim, Bang, Cho, Chung, Hwang, Hwang and Bae https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kim, Hyeon-Jong
Lee, Seung Hyuk
Shim, Hyun Jeong
Bang, Hyun Jin
Cho, Sang Hee
Chung, Ik-Joo
Hwang, Eu Chang
Hwang, Jun Eul
Bae, Woo Kyun
Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
title Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
title_full Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
title_fullStr Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
title_full_unstemmed Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
title_short Hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
title_sort hepatic arterial infusion chemotherapy versus systemic therapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597692/
https://www.ncbi.nlm.nih.gov/pubmed/37881486
http://dx.doi.org/10.3389/fonc.2023.1265240
work_keys_str_mv AT kimhyeonjong hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT leeseunghyuk hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT shimhyunjeong hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT banghyunjin hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT chosanghee hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT chungikjoo hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT hwangeuchang hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT hwangjuneul hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT baewookyun hepaticarterialinfusionchemotherapyversussystemictherapyforadvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis